Drug Profile
Research programme: ATPase inhibitors - Sigma Tau
Latest Information Update: 08 Aug 2007
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Class
- Mechanism of Action Adenosine triphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 03 Feb 1998 New profile
- 03 Feb 1998 Preclinical development for Hypertension in Italy (Unknown route)